A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.
A new study reveals that combinations of common food additives may increase the risk of Type 2 diabetes. Researchers analyzed data from over 108,000 adults, highlighting specific additive mixtures linked to health risks.
Recent research suggests that Ozempic and similar GLP-1 drugs may lower the risk of dementia in those with type 2 diabetes. Discover how these drugs are being tested for dementia prevention!
Novo Nordisk's diabetes pill Rybelsus has shown significant cardiovascular benefits, reducing the risk of heart-related issues by 14%. This could offer a new, convenient treatment option for many patients.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
After decades of lobbying, the US government is finally warning consumers about the dangers of ultra-processed foods. With new nutrition labels proposed, experts weigh in on their potential effectiveness and what more needs to be done to improve public health.
Discover how a new study suggests that Ozempic, a drug commonly used for diabetes and weight loss, may also help reduce alcohol consumption and cravings in individuals with alcohol-use disorder.
